Yazar "Kara, T." seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • Küçük Resim Yok
    Öğe
    Bone and peritoneal metastasis of breast carcinoma: findings on fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography
    (ELSEVIER SCIENCE INC, 2011) Kara, P. Ozcan; Kara, T.; Gedik, G. Kara; Sari, O.
    [Abstract not Available]
  • Küçük Resim Yok
    Öğe
    Comparison of bone scintigraphy and F-18-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases
    (ELSEVIER SCIENCE INC, 2011) Kara, P. Ozcan; Kara, T.; Gedik, G. Kara; Sari, O.; Sahin, O.
    A 62 year-old male with prostate cancer, recently complaining lumbar pain with elevated PSA level (6.83 ng/ml) was referred for evaluating bone metastases. Bone scintigraphy with Tc-99m-MDP demonstrated intense uptake on third lumbar vertebra. Postoperative biopsy of the lesion on third lumbar vertebra revealed adenocarcinoma metastasis. For evaluating distant metastases and restaging, F-18-FDG PET-CT was performed postoperatively. On PET-CT imaging there were cervical and left parailiac lymph nodes with FDG uptake, destruction on third lumbar vertebra level and intense soft tissue mass FOG uptake on the same area. Additionally, FDG uptake was detected on right iliac crest. On the CT images obtained by integrated PET-CT scanner, this uptake was matching with lytic bone metastases. The superiority of F-18-FDG PET-CT for demonstrating osteolytic bone metastases compared to bone scintigraphy was presented in a case of prostate cancer in a patient with bone and lymph node metastases. (C) 2010 Elsevier Espana, S.L. and SEMNIM. All rights reserved.
  • Küçük Resim Yok
    Öğe
    Do Standard Fields in the External Pelvic Radiotherapy of Cervical Carcinoma İnclude the Common İliac Lymph Nodes Sufficiently?
    (Elsevier Ireland Ltd, 2006) Yazıcı, G.; Kara, T.; Yıldız, F.; Özyar, E.; Cengiz, M.; Genç, M.; Demirkazak, F.
    [Abstract not Available]
  • Küçük Resim
    Öğe
    Evaluation of fluorine-18 Fluorodeoxyglucose uptake in lung hilus with positron emission tomography/computed tomography
    (SPRINGER, 2010) Gedik, G. Kara; Kara, P. Ozcan; Kara, T.; Sari, O.
    [Abstract not Available]
  • Küçük Resim
    Öğe
    Splenic and Multiple Abdominal Metastases of Endometrial Carcinoma Detected with FDG-PET/CT
    (ELSEVIER SCIENCE INC, 2012) Kara, T.; Kara, P. O.; Gedik, G. K.; Sarı, O.
    A 58 year old female was referred for FDG-PET/CT for restaging of endometrial adenocarcinoma. For evaluation of treatment, no metastases were detected on FDG-PET/CT which was performed 18 months later after the surgery. During follow-up, FDG-PET/CT was performed 6 months later than the previous FDG-PET/CT for restaging. A lesion with increased metabolic activity (SUV max: 10.21) was detected at spleen which was not seen on previous FDG-PET/CT scan. The lesion was consistent with metastasis of endometrial carcinoma. Splenic metastasis of endometrial carcinoma is extremely rare. There are only 13 cases of splenic metastasis from endometrial carcinoma that reported in the literature before. There is only one splenic metastasis of endometrial carcinoma case reported in the literature which is imaged with FDG-PET. To best of our knowledge this is the first report of solitary splenic metastasis of endometrial carcinoma that is imaged with FDG-PET/CT.
  • Küçük Resim
    Öğe
    The Value of FDG-PET/CT in the Post-Treatment Evaluation of Endometrial Carcinoma: A Comparison of PET/CT Findings with Conventional Imaging and CA 125 as a Tumour Marker
    (ELSEVIER DOYMA SL, 2012) Özcan Kara, P.; Kara, T.; Kaya, B.; Kara Gedik, G.; Sarı, O.
    Objectives: This retrospective study was designed to assess the value of positron emission tomography/computed tomography imaging (PET/CT) in the post-treatment evaluation of the patients with endometrial carcinoma and to compare PET/CT scan with conventional imaging (Cl) including computed tomography (CT), ultrasonography (US) and magnetic resonance imaging (MRI) and CA 125 with both 20 U/ml and 35 U/ml cut-off values. Materials and methods: A total of 31 patients who were treated for histopathologically proven endometrial adenocarcinoma, underwent PET/CT examination for restaging and suspected recurrence. Thirty five PET/CT studies were performed in 31 patients. Lesion status was determined on the basis of clinical follow-up including radiological imaging (follow-up CT scan) at least 6 months and response to therapy. Results: Of the 35 PET/CT studies, 13 (37%) studies were positive, whereas 22 (63%) of them were negative. On study-based analysis the overall sensitivity, specificity, accuracy for PET/CT imaging were 100%, 96% and 97%, respectively. The corresponding information for Cl were 46%, 87% and 74%, for CA 125 (cut off= 20 U/ml) measurement were 45%, 88% and 74%, and for CA 125 (cut off = 35 U/ml) measurement were 27%, 100% and 78%, respectively. On lesion-based analysis, PET/CT revealed only one false positive case. In none of 21 patients with negative 22 PET/CT studies, no subsequent clinical or radiological recurrences were observed with a follow-up of at least 6 months. Conclusion: FDG-PET/CT is found more useful modality than CI and CA 125 in the evaluation of post-treatment endometrial carcinoma patients, for suspected recurrence.